Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
78
CPIX Quote, Financials, Valuation and Earnings
Last price:
$4.11
Seasonality move
:
6.08%
Day range:
$4.05 - $4.27
52-week range:
$1.85 - $7.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.48x
P/B ratio:
2.36x
Volume:
119.4K
Avg. volume:
168.9K
1-year change:
75.32%
Market cap:
$61.6M
Revenue:
$37.9M
EPS (TTM):
-$0.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CPIX
Cumberland Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.84% | 39.23% | $110.04 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CPIX
Cumberland Pharmaceuticals, Inc.
|
$4.12 | -- | $61.6M | -- | $0.00 | 0% | 1.48x |
|
MRK
Merck & Co., Inc.
|
$106.78 | $110.04 | $265B | 14.13x | $0.85 | 3.07% | 4.21x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
OGEN
Oragenics, Inc.
|
$0.86 | $2.00 | $706.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CPIX
Cumberland Pharmaceuticals, Inc.
|
28.16% | -4.884 | 22.09% | 1.05x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CPIX
Cumberland Pharmaceuticals, Inc.
|
$6.3M | -$2M | -8.27% | -12.95% | -23.58% | $155K |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Cumberland Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns CPIX or MRK?
Merck & Co., Inc. has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of 33.68%. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital CPIXCumberland Pharmaceuticals, Inc.75.56% -$0.13 $36M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About CPIX or MRK?
Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 106.31%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.05%. Given that Cumberland Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Cumberland Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPIXCumberland Pharmaceuticals, Inc.0 0 0 MRKMerck & Co., Inc.15 12 0 -
Is CPIX or MRK More Risky?
Cumberland Pharmaceuticals, Inc. has a beta of -0.455, which suggesting that the stock is 145.505% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock CPIX or MRK?
Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.07% to investors and pays a quarterly dividend of $0.85 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CPIX or MRK?
Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.48x versus 4.21x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPIXCumberland Pharmaceuticals, Inc.1.48x -- $8.3M -$1.9M MRKMerck & Co., Inc.4.21x 14.13x $17.2B $5.8B
-
Which has Higher Returns CPIX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of -255.85%. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CPIXCumberland Pharmaceuticals, Inc.75.56% -$0.13 $36M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CPIX or NBY?
Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 106.31%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Cumberland Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cumberland Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPIXCumberland Pharmaceuticals, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CPIX or NBY More Risky?
Cumberland Pharmaceuticals, Inc. has a beta of -0.455, which suggesting that the stock is 145.505% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CPIX or NBY?
Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPIX or NBY?
Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.48x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPIXCumberland Pharmaceuticals, Inc.1.48x -- $8.3M -$1.9M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns CPIX or OGEN?
Oragenics, Inc. has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of --. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital CPIXCumberland Pharmaceuticals, Inc.75.56% -$0.13 $36M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About CPIX or OGEN?
Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 106.31%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 132.83%. Given that Oragenics, Inc. has higher upside potential than Cumberland Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than Cumberland Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPIXCumberland Pharmaceuticals, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is CPIX or OGEN More Risky?
Cumberland Pharmaceuticals, Inc. has a beta of -0.455, which suggesting that the stock is 145.505% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock CPIX or OGEN?
Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPIX or OGEN?
Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are larger than Oragenics, Inc. quarterly revenues of --. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.48x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPIXCumberland Pharmaceuticals, Inc.1.48x -- $8.3M -$1.9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns CPIX or PTN?
Palatin Technologies has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of --. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CPIXCumberland Pharmaceuticals, Inc.75.56% -$0.13 $36M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CPIX or PTN?
Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 106.31%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Cumberland Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Cumberland Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPIXCumberland Pharmaceuticals, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is CPIX or PTN More Risky?
Cumberland Pharmaceuticals, Inc. has a beta of -0.455, which suggesting that the stock is 145.505% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CPIX or PTN?
Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPIX or PTN?
Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are larger than Palatin Technologies quarterly revenues of --. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Palatin Technologies's net income of --. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.48x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPIXCumberland Pharmaceuticals, Inc.1.48x -- $8.3M -$1.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CPIX or TOVX?
Theriva Biologics, Inc. has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of --. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CPIXCumberland Pharmaceuticals, Inc.75.56% -$0.13 $36M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CPIX or TOVX?
Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 106.31%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Cumberland Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Cumberland Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPIXCumberland Pharmaceuticals, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CPIX or TOVX More Risky?
Cumberland Pharmaceuticals, Inc. has a beta of -0.455, which suggesting that the stock is 145.505% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock CPIX or TOVX?
Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPIX or TOVX?
Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.48x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPIXCumberland Pharmaceuticals, Inc.1.48x -- $8.3M -$1.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
